SG11202104031RA - Crystalline forms of mnk inhibitors - Google Patents
Crystalline forms of mnk inhibitorsInfo
- Publication number
- SG11202104031RA SG11202104031RA SG11202104031RA SG11202104031RA SG11202104031RA SG 11202104031R A SG11202104031R A SG 11202104031RA SG 11202104031R A SG11202104031R A SG 11202104031RA SG 11202104031R A SG11202104031R A SG 11202104031RA SG 11202104031R A SG11202104031R A SG 11202104031RA
- Authority
- SG
- Singapore
- Prior art keywords
- crystalline forms
- mnk inhibitors
- mnk
- inhibitors
- crystalline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749820P | 2018-10-24 | 2018-10-24 | |
| PCT/US2019/057656 WO2020086713A1 (en) | 2018-10-24 | 2019-10-23 | Crystalline forms of mnk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104031RA true SG11202104031RA (en) | 2021-05-28 |
Family
ID=70326420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104031RA SG11202104031RA (en) | 2018-10-24 | 2019-10-23 | Crystalline forms of mnk inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11130757B2 (en) |
| EP (1) | EP3870178A4 (en) |
| JP (1) | JP2022505846A (en) |
| KR (1) | KR20210102211A (en) |
| CN (1) | CN113286592A (en) |
| AU (1) | AU2019366947A1 (en) |
| BR (1) | BR112021007745A2 (en) |
| CA (1) | CA3117169A1 (en) |
| IL (1) | IL282552A (en) |
| MX (1) | MX2021004763A (en) |
| SG (1) | SG11202104031RA (en) |
| TW (1) | TW202035405A (en) |
| WO (1) | WO2020086713A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019016707A2 (en) | 2017-02-14 | 2020-04-07 | Effector Therapeutics Inc | mnk inhibitors replaced by piperidine and methods related to them |
| BR112021007745A2 (en) | 2018-10-24 | 2021-07-27 | Effector Therapeutics, Inc. | crystalline forms of mnk inhibitors |
| BR112022026275A2 (en) * | 2020-06-30 | 2023-03-14 | 4E Therapeutics Inc | PYRIDINE-1,5-DIONES THAT EXHIBIT MNK INHIBITION AND THEIR METHODS OF USE |
| EP4200296A1 (en) * | 2020-08-20 | 2023-06-28 | Hepagene Therapeutics (HK) Limited | Mnk inhibitors |
| US11925642B2 (en) | 2020-10-08 | 2024-03-12 | Board Of Regents, The University Of Texas System | Regulation of eIF4E activity for migraine therapy |
| CN114736205B (en) * | 2022-03-31 | 2023-03-03 | 武汉九州钰民医药科技有限公司 | Preparation method of compound Tomivosertib |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5491144A (en) | 1991-05-30 | 1996-02-13 | Ciba-Geigy Corporation | Substituted diaminophthalimides and analogues |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| CA2445620C (en) | 2001-06-05 | 2008-07-08 | Lilly Icos Llc | Tetracyclic compounds as pde5-inhibitors |
| ES2359233T3 (en) | 2001-10-29 | 2011-05-19 | Boehringer Ingelheim International Gmbh | HOMOLOGICAL PROTEINS OF THE MNK KINASE INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANULAR METABOLISM. |
| US20050012622A1 (en) | 2003-05-19 | 2005-01-20 | Sutton William R. | Monitoring and control of sleep cycles |
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2006135783A2 (en) | 2005-06-10 | 2006-12-21 | Wisconsin Alumni Research Foundation | Compositions and methods for modulating angiogenesis |
| CN101277934A (en) | 2005-08-12 | 2008-10-01 | 阿斯利康(瑞典)有限公司 | Metabotropic glutamate-receptor-potentiating isoindolones |
| CN101472912A (en) | 2006-06-22 | 2009-07-01 | 比奥维特罗姆上市公司 | Pyridine and pyrazine derivatives as MNK kinase inhibitors |
| EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
| WO2008115369A2 (en) | 2007-03-16 | 2008-09-25 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| CA2706203A1 (en) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Use of mnk inhibitors for the treatment of alzheimer's disease |
| JP2009173629A (en) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | New spiroindane derivative having rsk1 inhibition |
| WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
| BRPI0918971A2 (en) | 2008-08-26 | 2015-12-01 | Boehringer Ingelheim Int | thienopyrimidines for pharmaceutical compositions |
| WO2010055072A2 (en) | 2008-11-12 | 2010-05-20 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating a mnk |
| TWI468402B (en) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | Compounds for the reduction of β-amyloid production |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| EP2462123B1 (en) | 2009-08-04 | 2013-10-02 | Merck Sharp & Dohme Corp. | 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| US8604217B2 (en) | 2009-11-12 | 2013-12-10 | Selvita S.A. | Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| WO2011106168A1 (en) | 2010-02-24 | 2011-09-01 | Dcam Pharma Inc | Purine compounds for treating autoimmune and demyelinating diseases |
| KR20130099117A (en) | 2010-10-01 | 2013-09-05 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | Substituted n-(2-arylamino)aryl sulfonamide-containing combinations |
| CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
| JOP20120083B1 (en) * | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013043192A1 (en) | 2011-09-23 | 2013-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders |
| PL2797927T3 (en) | 2011-12-30 | 2019-12-31 | Hanmi Pharm. Co., Ltd. | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES |
| EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| CA2873971A1 (en) | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyrimidines |
| TW201412740A (en) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | Substituted pyrrolopyrimidinylamino-benzothiazolones |
| WO2014072244A1 (en) | 2012-11-09 | 2014-05-15 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| GB2508652A (en) | 2012-12-07 | 2014-06-11 | Agency Science Tech & Res | Heterocyclic piperazine derivatives |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| CA2901527A1 (en) | 2013-02-20 | 2014-08-28 | Bayer Pharma Aktiengesellschaft | Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors |
| KR101858913B1 (en) | 2013-02-21 | 2018-05-16 | 화이자 인코포레이티드 | Solid forms of a selective cdk4/6 inhibitor |
| TW201605867A (en) | 2013-11-20 | 2016-02-16 | 拜耳製藥公司 | Thienopyrimidines |
| EA036325B1 (en) | 2014-03-14 | 2020-10-27 | Аджиос Фармасьютикалз, Инк. | Pharmaceutical composition comprising solid dispersion of idh1 inhibitor |
| TWI713455B (en) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | Mnk inhibitors and methods related thereto |
| WO2016096721A1 (en) | 2014-12-19 | 2016-06-23 | Bayer Pharma Aktiengesellschaft | Pyrazolopyridinamines as mknk1 and mknk2 inhibitors |
| US10702526B2 (en) * | 2015-04-20 | 2020-07-07 | Effector Therapeutics Inc. | Inhibitors of immune checkpoint modulators and related methods |
| EA034440B1 (en) | 2015-10-29 | 2020-02-07 | Эффектор Терапьютикс, Инк. | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT Mnk1 AND Mnk2 |
| CN108602805A (en) | 2015-10-29 | 2018-09-28 | 效应治疗股份有限公司 | Isoindoline, azaisoindoline, indenone and the dihydro azepine indone inhibitor of MNK1 and MNK2 |
| GB201520500D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
| GB201520499D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
| WO2017117052A1 (en) * | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
| BR112019012140A2 (en) | 2016-12-19 | 2019-11-05 | Epizyme Inc | compound, pharmaceutical composition, method for preventing or treating a blood disorder, method for preventing or treating cancer, and use of a compound |
| TW201831479A (en) * | 2017-01-20 | 2018-09-01 | 德商拜耳製藥公司 | Substituted dihydroimidazopyridinediones |
| BR112019016707A2 (en) | 2017-02-14 | 2020-04-07 | Effector Therapeutics Inc | mnk inhibitors replaced by piperidine and methods related to them |
| CA3064000A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
| JP2021503478A (en) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | Combination treatment |
| WO2019103926A1 (en) * | 2017-11-21 | 2019-05-31 | Saint Louis University | P38 inhibitors for the treatment of fshd |
| BR112021007745A2 (en) | 2018-10-24 | 2021-07-27 | Effector Therapeutics, Inc. | crystalline forms of mnk inhibitors |
-
2019
- 2019-10-23 BR BR112021007745-6A patent/BR112021007745A2/en unknown
- 2019-10-23 TW TW108138191A patent/TW202035405A/en unknown
- 2019-10-23 EP EP19877103.2A patent/EP3870178A4/en active Pending
- 2019-10-23 MX MX2021004763A patent/MX2021004763A/en unknown
- 2019-10-23 SG SG11202104031RA patent/SG11202104031RA/en unknown
- 2019-10-23 KR KR1020217015288A patent/KR20210102211A/en unknown
- 2019-10-23 JP JP2021522525A patent/JP2022505846A/en active Pending
- 2019-10-23 AU AU2019366947A patent/AU2019366947A1/en active Pending
- 2019-10-23 CN CN201980069872.4A patent/CN113286592A/en active Pending
- 2019-10-23 US US16/661,507 patent/US11130757B2/en active Active
- 2019-10-23 WO PCT/US2019/057656 patent/WO2020086713A1/en unknown
- 2019-10-23 CA CA3117169A patent/CA3117169A1/en active Pending
-
2021
- 2021-04-22 IL IL282552A patent/IL282552A/en unknown
- 2021-09-24 US US17/484,564 patent/US11952375B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL282552A (en) | 2021-06-30 |
| US11130757B2 (en) | 2021-09-28 |
| TW202035405A (en) | 2020-10-01 |
| WO2020086713A1 (en) | 2020-04-30 |
| EP3870178A4 (en) | 2022-08-03 |
| AU2019366947A1 (en) | 2021-06-03 |
| JP2022505846A (en) | 2022-01-14 |
| EP3870178A1 (en) | 2021-09-01 |
| MX2021004763A (en) | 2021-06-08 |
| BR112021007745A2 (en) | 2021-07-27 |
| US20220119387A1 (en) | 2022-04-21 |
| KR20210102211A (en) | 2021-08-19 |
| US11952375B2 (en) | 2024-04-09 |
| CA3117169A1 (en) | 2020-04-30 |
| US20200131179A1 (en) | 2020-04-30 |
| CN113286592A (en) | 2021-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291430A (en) | Mcl-1 inhibitors | |
| IL282552A (en) | Crystalline forms of mnk inhibitors | |
| IL271028A (en) | Inhibition of crystal growth of roflumilast | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| IL281939A (en) | Inhibitors of vap-1 | |
| EP3801503A4 (en) | Inhibitors of sarm1 | |
| IL281815A (en) | Inhibitors of vap-1 | |
| IL276592A (en) | Derivatives of sobetirome | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| PL3532457T3 (en) | Crystalline forms of hydroxynorketamine | |
| EP3801500A4 (en) | Inhibitors of sarm1 | |
| EP3801499A4 (en) | Inhibitors of sarm1 | |
| SI3749673T1 (en) | Crystalline form of bictegravir sodium | |
| IL277806A (en) | Growth inhibitor | |
| IL270961A (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
| IL269792B (en) | Crystalline forms of (s)-afoxolaner | |
| EP3801525A4 (en) | Inhibitors of prolyl-trna-synthetase | |
| EP3793980A4 (en) | Crystalline form of s-apomorphine | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL277869A (en) | Substituted propanamides as inhibitors of nucleases | |
| IL277578A (en) | Novel salt forms of urat-1 inhibitors | |
| IL277866A (en) | Substituted aminothiazoles as inhibitors of nucleases | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| SG11202108905UA (en) | Crystalline form of an avibactam derivative | |
| SG11202106210QA (en) | Salt of syk inhibitor and crystalline form thereof |